This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.
Has subjective or objective cognitive impairment
Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member)
Sufficient proficiency in English or French to undertake self report and neuropsychological testing
Geographic accessibility to the study site
The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses
Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
Symptomatic stroke within the previous year
Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure
2300 English and/or French-speaking participants recruited from across Canada in the following groups: * 650 Cognitively healthy volunteers * 300 volunteers with Subjective Cognitive Decline * 400 volunteers with Mild Cognitive Impairment * 200 volunteers with Vascular Mild Cognitive Impairment * 150 volunteers with Alzheimer's disease * 200 volunteers with Dementia of Mixed Etiology * 200 volunteers with Parkinson's disease and cognitive impairment * 200 volunteers with Frontotemporal spectrum dementia
Cohort
Prospective
Not listed
8
Trial groupsSee each trial group below.
Montreal Cognitive Assessment (MoCA) score
change in MoCA total score. The MoCA is a test of global cognition scored out of 30 with a higher score indicating better performance. The minimum score is 0 and the maximum score is 30.
Click on the lead sponsor to view all of their trials.
McGill University
Lead sponsor
Baycrest
Sponsor institution
Canadian Institutes of Health Research (CIHR)
Collaborator
Alzheimer Society of Canada
Collaborator
Sanofi
Collaborator
New Brunswick Health Research Foundation
Collaborator
Saskatchewan Health Research Foundation
Collaborator
Michael Smith Foundation for Health Research
Collaborator
Nova Scotia Health Research Foundation
Collaborator
Eli Lilly and Company
Collaborator
Canadian Nurses Foundation (CNF)
Collaborator
Ontario Brain Institute
Collaborator
Pfizer
Collaborator
Canadian Consortium on Neurodegeneration in Aging
Collaborator
